Tag Archives: Alethia Young

Cantor Fitzgerald Sticks to Its Hold Rating for Regeneron (REGN)

Cantor Fitzgerald analyst Alethia Young reiterated a Hold rating on Regeneron (REGN – Research Report) yesterday and set a price target of $441. The company’s shares closed on Friday at $406.86, close to its 52-week high of $431.32. Young said:

Cantor Fitzgerald Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)

Cantor Fitzgerald analyst Alethia Young reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report) yesterday and set a price target of $135. The company’s shares closed yesterday at $80.80. Young wrote: “: We reiterate our Overweight rating and

Analysts Are Bullish on Top Healthcare Stocks: Sarepta Therapeutics (SRPT), Orthofix (OFIX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report) and Orthofix (OFIX – Research Report) with bullish sentiments. Sarepta Therapeutics (SRPT) In a report released

Regeneron (REGN) Gets a Hold Rating from Cantor Fitzgerald

In a report released today, Alethia Young from Cantor Fitzgerald assigned a Hold rating to Regeneron (REGN – Research Report), with a price target of $441. The company’s shares closed yesterday at $421.04, close to its 52-week high of $431.32.

Cantor Fitzgerald Sticks to Its Buy Rating for Xencor Inc (XNCR)

In a report released today, Alethia Young from Cantor Fitzgerald reiterated a Buy rating on Xencor Inc (XNCR – Research Report), with a price target of $40. The company’s shares opened today at $37.50. Young commented: “we reiterate our Overweight

Intercept Pharma (ICPT) Received its Third Buy in a Row

After Cowen & Co. and Laidlaw gave Intercept Pharma (NASDAQ: ICPT) a Buy rating last month, the company received another Buy, this time from Cantor Fitzgerald. Analyst Alethia Young maintained a Buy rating on Intercept Pharma yesterday and set a